myeloma for preventing bone disease or managing non-spinal bone disease. Denosumab (Xgeva®) is a monoclonal antibody that targets receptor activator of nuclear factor kappa-B …

The following Systemic Anti-Cancer Therapy (SACT) clinical protocols and guidance have been developed by local clinicians, with support from the Somerset, Wiltshire, Avon and …

Myeloma MDT referral: Proforma (H.77) Instructions (H.77a) MDT Referral ACE27 Comorbidity Scoresheet (OPTIONAL) Example letter to Dentist (H.83b) Adult Haematology Long-term …

• Myeloma IX trial demonstrated that zoledronic acid significantly reduces skeletal events and may improve survival when compared with clodronate. 7 • Intravenous zoledronate 4 mg monthly is …

malignancies for the Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Network Cancer of Unknown Primary Site Specific Group (NSSG). The NSSG refers to the National Institute for …

• Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone Indication • Daratumumab in combination with lenalidomide and dexamethasone is recommended for use within the Cancer …

myeloma for preventing bone disease or managing non-spinal bone disease. Denosumab (Xgeva®) is a monoclonal antibody that targets receptor activator of nuclear factor kappa-B …

Authorised by Myeloma lead Dr. Jaimal Kothari June 2023 V.3.0 1 of 12 CARFILZOMIB with LENALIDOMIDE and DEXAMETHASONE (KRD) INDICATIONS Multiple myeloma at first …

Treatment of relapsed and refractory multiple myeloma after 3 or more lines of treatment (including an immunomodulatory agent (IMID), proteasome inhibitor (PI) and anti-CD38 …

This Treatment Guide contains information about elranatamab, a treatment used in myeloma. This publication is part of our Treatment Guide series, a collection of booklets covering the different …